The success rate for treating multidrug-resistant tuberculosis (MDR-TB) in the US is projected to steadily increase from 89% in 2024 to 93% by 2028. In 2023, the treatment success rate was observed at a lower rate than 2024, indicating positive advancements in treatment strategies. The year-on-year improvement from 2024 through 2028 highlights a consistent enhancement in treatment efficacy. The five-year compound annual growth rate (CAGR) underscores sustained progress.
Future trends to monitor include the development of more effective drug regimens, the impact of technological improvements in diagnostics, the role of personalized medicine approaches, and public health initiatives focused on MDR-TB management. These factors could further facilitate treatment success and patient outcomes.
